Cation/proton antiporters: novel structure-driven pharmaceutical opportunities

Gal Masrati, Amit Kessel, Nir Ben-Tal*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review


Cation/proton antiporters (CPAs) regulate cells’ salt concentration and pH. Their malfunction is associated with a range of human pathologies, yet only a handful of CPA-targeting therapeutics are presently in clinical development. Here, we discuss how recently published mammalian protein structures and emerging computational technologies may help to bridge this gap.

Original languageEnglish
Pages (from-to)258-262
Number of pages5
JournalTrends in Pharmacological Sciences
Issue number5
StatePublished - May 2023


FundersFunder number
NATO Science for Peace and Security Program
Saudi Pharmaceutical SocietyG5685
Tel Aviv University


    • cation/proton antiporters
    • computational biology
    • pharmacology


    Dive into the research topics of 'Cation/proton antiporters: novel structure-driven pharmaceutical opportunities'. Together they form a unique fingerprint.

    Cite this